Maintain pressure on reforms to protect NHSChemotherapy drug may increase kidney damage risk
The chemotherapy drug bevacizumab (Avastin) may put cancer patients at increased risk of severe kidney damage, according to US research.
The study, which involved more than 12,000 patients, found the drug could put patients at increased risk of severe loss of protein from the kidney into the urine, potentially leading to significant kidney damage.
The research, carried out by the Stony Brook University Medical Centre in Stony Brook, New York, is reported in the Journal of the American Society Nephrology.
Online training units, written and reviewed by experts. Earn two hours' CPD and a personalised certificate for your portfolio.
Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.
Share
Have your say
You must sign in to make a comment.